Oxigene -

Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.

Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor. Oxigene

In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million. Investigated as a topical or systemic treatment to

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions: OXiGENE acquired VaxGen

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)